DS
CTIC

David Shaw’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

David Shaw’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-34,578
Closed -$201K – 5596
2022
Q3 		$201K Sell
34,578
-69,261
-67% -$432K ﹤0.01% 4474
2022
Q2 		$620K Buy
+103,839
New +$532K ﹤0.01% 3973
2020
Q3 		– Sell
-13,207
Closed -$15K – 4366
2020
Q2 		$15K Buy
+13,207
New +$13.9K ﹤0.01% 3942
2019
Q4 		– Sell
-21,396
Closed -$18K – 4318
2019
Q3 		$18K Buy
21,396
+10,094
+89% +$7.71K ﹤0.01% 3758
2019
Q2 		$10K Hold
11,302
– – ﹤0.01% 3628
2019
Q1 		$11K Hold
11,302
– – ﹤0.01% 3545
2018
Q4 		$8K Hold
11,302
– – ﹤0.01% 3716
2018
Q3 		$24K Buy
+11,302
New +$28K ﹤0.01% 3677
2017
Q1 		– Sell
-2,326
Closed -$9K – 3810
2016
Q4 		$9K Sell
2,326
-930
-29% -$3.86K ﹤0.01% 3403
2016
Q3 		$12K Buy
3,256
+1,930
+146% +$7.03K ﹤0.01% 3339
2016
Q2 		$5K Buy
+1,326
New +$6.08K ﹤0.01% 3317
2016
Q1 		– Sell
-1,549
Closed -$19K – 4088
2015
Q4 		$19K Buy
1,549
+405
+35% +$5.41K ﹤0.01% 3745
2015
Q3 		$17K Sell
1,144
-1,262
-52% -$21.8K ﹤0.01% 3685
2015
Q2 		$47K Sell
2,406
-1,579
-40% -$30.5K ﹤0.01% 3692
2015
Q1 		$72K Buy
3,985
+440
+12% +$9.9K ﹤0.01% 3546
2014
Q4 		$84K Sell
3,545
-486
-12% -$11.2K ﹤0.01% 3918
2014
Q3 		$98K Buy
+4,031
New +$105K ﹤0.01% 3984
2014
Q2 		– Sell
-1,237
Closed -$42K – 4881
2014
Q1 		$42K Sell
1,237
-41,509
-97% -$1.42M ﹤0.01% 4206
2013
Q4 		$821K Sell
42,746
-8,715
-17% -$159K ﹤0.01% 3341
2013
Q3 		$843K Sell
51,461
-52,805
-51% -$612K ﹤0.01% 3187
2013
Q2 		$1.09M Buy
+104,266
New +$1.22M ﹤0.01% 2634

Other funds holding CTIC

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

David Shaw's CTIC Position: Q4 2022 in Review

David Shaw sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q4 2022, closing a stake of 34,578 shares — an estimated $201K sold.

David Shaw first reported a position in CTIC in Q2 2013 and held it in 21 quarters. The position peaked at $1.09M in Q2 2013. 145 funds tracked by Wall St. Rank hold CTIC as of Q4 2022.

  • David Shaw reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q4 2022 after selling out during the quarter.
  • David Shaw sold 34,578 CTI BioPharma Corp. (DE) Common Stock shares in Q4 2022, an estimated $201K.
  • David Shaw first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2013 and held it in 21 quarters.
  • David Shaw's CTI BioPharma Corp. (DE) Common Stock position peaked at $1.09M in Q2 2013.
  • 145 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q4 2022.

Based on D.E. Shaw & Co's 13F filing for Q4 2022, filed 14 Feb 2023.